Key facts
- Notable investors include Jumar Bioincubator, Uniseed.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Nelcanen Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Nelcanen Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nelcanen Therapeutics
Developer of therapeutics designed to address conditions at the intersection of inflammation, autoimmunity, and fibrosis. The company focuses on creating novel drug candidates, advancing research programs, conducting preclinical development, exploring mechanisms of immune regulation, targeting pathways involved in chronic disease progression, and building a pipeline of therapies, enabling healthcare providers, research institutions, and patients to access innovative treatment options that aim to improve clinical outcomes, reduce disease burden, and expand therapeutic possibilities in complex immune-mediated disorders.
- Sector
- Healthcare
- HQ
- Melbourne, Australia
- Founded
- 2025
- Employees
- 2
- Website
- nelcanen.com/
- Ownership
- Privately Held (backing)
Nelcanen Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nelcanen Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nelcanen Therapeutics in its N-PORT filings yet. We sweep new filings monthly.